Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

Abstract

During a median follow up of 2 years sustained response to infliximab was observed in slightly more than half of CD patients. Infliximab TL>3μg/ml at the start of maintenance regime were predicative of sustained response to infliximab.